Mirum(US:MIRM)2025-11-04 21:02Revenue Performance - Third quarter 2025 total revenue was $133 million, compared to $90.4 million for the same quarter in 2024, representing a 47% year-over-year increase[4] - LIVMARLI net product sales for the third quarter 2025 were $92.2 million, reflecting a 56% growth over the third quarter 2024[4] - Bile Acid Medicines net product sales for the third quarter 2025 were $40.8 million, indicating a 31% increase compared to the same period in 2024[4] - Total revenue for the three months ended September 30, 2025, was $133.01 million, a 47.2% increase from $90.38 million in the same period of 2024[26] - Product sales, net for the nine months ended September 30, 2025, reached $372.38 million, compared to $236.98 million in 2024, reflecting a 57.1% growth[26] Financial Guidance and Expenses - The updated revenue guidance for 2025 is between $500 million and $510 million[1] - Total operating expenses for the third quarter 2025 were $130.4 million, up from $103.1 million in the same quarter of 2024[4] - Research and development expenses for the three months ended September 30, 2025, were $42.96 million, up 35.4% from $31.71 million in 2024[26] - The company incurred total stock-based compensation expenses of $18.13 million for the three months ended September 30, 2025, compared to $11.91 million in the same period of 2024, a 52.5% increase[26] Income and Assets - Net income for the three months ended September 30, 2025, was $2.91 million, compared to a net loss of $14.24 million in the same period of 2024[26] - Total current assets increased to $530.58 million as of September 30, 2025, from $392.79 million at the end of 2024, representing a 35.1% increase[28] - Cash and cash equivalents rose to $282.02 million as of September 30, 2025, compared to $222.50 million at the end of 2024, a 26.8% increase[28] - Total stockholders' equity increased to $292.05 million as of September 30, 2025, from $225.64 million at the end of 2024, reflecting a 29.3% growth[28] - Total liabilities as of September 30, 2025, were $493.07 million, up from $445.11 million at the end of 2024, indicating an increase of 10.8%[28] - The company reported a basic net income per share of $0.06 for the three months ended September 30, 2025, compared to a loss of $0.30 per share in the same period of 2024[26] Clinical Studies and Trials - Enrollment in the Volixibat VISTAS study for primary sclerosing cholangitis (PSC) is complete, with topline data expected in the second quarter of 2026[4] - The Phase 2 study for MRM-3379 in Fragile X Syndrome has been initiated[4] - The Volixibat VANTAGE study in primary biliary cholangitis (PBC) is expected to complete enrollment in 2026, with topline data anticipated in the first half of 2027[4] - LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is expected to complete enrollment in 2026, with topline data expected in the first half of 2027[4]